Everyone aged 50 to 74 in England is now offered a home test for bowel cancer, after the NHS completed the expansion of its screening programme in March 2025. People aged 50 and 52 began receiving the faecal immunochemical test, or FIT, automatically by post, completing a phased rollout that began in 2021, when screening was offered only to people aged 60 and over. Around 850,000 more people a year are now eligible, and more than four million extra people have been invited since the expansion began. The test looks for tiny traces of blood in a small stool sample, which can be an early sign of bowel cancer, and it is done at home every two years. Bowel cancer is the fourth most common cancer in Britain, with around 44,000 people diagnosed each year, and it is highly treatable when caught early: more than nine in ten people survive for five years or more when the disease is found at its earliest stage, compared with about one in ten when it is found late. Screening can also prevent cancer, because it finds polyps, small growths that can be removed before they turn cancerous.
What the Evidence Shows
The test itself is simple and takes a few minutes: a small stick collects a sample, which is sealed in a tube and posted back in a prepaid envelope, and most people get a normal result within two weeks. About two in every hundred tests come back abnormal, which does not mean cancer, but leads to a hospital appointment for a colonoscopy, a camera examination of the bowel. Uptake is the challenge: only about seven in ten people invited return the test, and rates are lower in deprived areas and among some ethnic groups, which is why the NHS is working with community groups to raise awareness. Anyone who receives a kit should use it, and anyone with symptoms such as blood in the stool, a persistent change in bowel habit or unexplained weight loss should see a doctor straight away, whatever their age. Reporting and analysis from sources such as National Institutes of Health track the same developments, and specialists following bowel cancer screening say the direction is now consistent across independent lines of evidence.
The Wider Context
The wider context is a health system trying to move from treating illness late to preventing it early, against budgets that reward the opposite. Evidence around bowel cancer screening is being weighed by guideline committees that ask two questions in order: does it work, and can ordinary services actually deliver it at scale. Many good ideas pass the first test and stall on the second.
What Happens Next
What happens next for bowel cancer screening depends on the slow machinery of guidelines, funding and training catching up with the evidence. Patients asking about it today should expect honest answers that include uncertainty, and clinicians say a service that explains what is not yet known earns more trust than one that oversells. The research pipeline, at least, is moving in the right direction. You can follow related developments in our coverage of health.
None of this will be settled by a single announcement, study or product launch. The pattern to watch is accumulation: independent confirmations, honest reporting of failures and steady improvement in the underlying numbers. Readers who follow those signals, rather than the loudest claim of the week, will understand this subject better than most of the commentary surrounding it suggests is possible.
